INTRODUCTION: Renal ischemia-reperfusion injury (IRI) is a major cause of acute kidney injury (AKI), but specific therapeutic targets are lacking.Lysosomal Protein Transmembrane 4A (LAPTM4A), a four transmembrane-spanning protein mainly localized in endosomes and lysosomes,however, its pathological role in AKI remains unexplored. METHODS: To investigate the impact of LAPTM4A on renal IRI, we developed an in vivo renal IRI model utilizing LAPTM4A knockout mice, alongside an in vitro hypoxia-reperfusion(H/R) model employing shRNA to knockdown LAPTM4A in HK2 cell. A comprehensive suite of methodologies, including Western blotting, qPCR, CCK-8 assay, LDH assay, TUNEL assay, ELISA, and histopathological analysis, was employed to evaluate cell proliferation, apoptosis, and inflammatory cytokine levels. RESULTS: We found that the expression of Laptm4a was upregulated in kidney of renal IRI mice and HK2 cell induced by hypoxia-reoxygenation(H/R). Knockout of Laptm4a improved renal function , attenuated tubular injury and reduced inflammatory cell infiltration and apoptosis, whereas overexpression exacerbated the injury.Mechanistically Laptm4a exacerbated renal IRI through suppression of the UNC5B-AKT-mTOR protective signaling pathway. CONCLUSIONS: Our findings suggest that Laptm4a exacerbates inflammation and apoptosis by inhibiting the UNC5B-PI3K-AKT signaling pathway. This study provides a novel elucidation of the role of Laptm4a as a critical positive regulator of IRI, offering preliminary preclinical insights that may inform future investigations into therapeutic strategies.
Laptm4a mediates renal ischemia-reperfusion injury by regulating the UNC5B-AKT/mTOR signaling pathway.
Laptm4a 通过调节 UNC5B-AKT/mTOR 信号通路介导肾脏缺血再灌注损伤。
阅读:2
| 期刊: | Frontiers in Immunology | 影响因子: | 5.900 |
| 时间: | 2026 | 起止号: | 2026 Mar 24; 17:1683343 |
| doi: | 10.3389/fimmu.2026.1683343 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。